- Home
- FRGE vs ATXS Comparison
FRGE vs ATXS Comparison
Compare FRGE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRGE | ATXS |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.4M | 721.6M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FRGE | ATXS |
|---|---|---|
| Price | $44.57 | $12.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $31.00 | $24.33 |
| AVG Volume (30 Days) | 451.9K | ★ 1.4M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,884,000.00 | $706,000.00 |
| Revenue This Year | $33.10 | N/A |
| Revenue Next Year | $24.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.40 | N/A |
| 52 Week Low | $6.60 | $3.56 |
| 52 Week High | $44.76 | $13.29 |
Technical Indicators
Market Signals| Indicator | FRGE | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 85.45 | 58.07 |
| Support Level | $44.30 | $12.64 |
| Resistance Level | $44.75 | $13.14 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | -0.75 | -0.08 |
| Stochastic Oscillator | 67.27 | 32.14 |
Price Performance
Historical ComparisonAbout FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.